NASDAQ$ITOS
iTeos Therapeutics Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2020 and provided recent business highlights.
iTeos Therapeutics reported its Q2 2020 financial results, highlighting the completion of its IPO in July, which provided $210.6 million in net proceeds and extends the company's cash runway into 2023. Clinical trials for EOS-850 and EOS-448 are ongoing, with initial data expected in the first half of 2021.
- Completed IPO in July 2020, raising $229.7 million in gross proceeds.
- Net proceeds from the IPO were $210.6 million, extending cash runway into 2023.
- Enrollment continues in Phase 1/2a clinical trials for EOS-850 and EOS-448.
- Initial data from monotherapy and combination therapy cohorts of EOS-850 and EOS-448 expected in the first half of 2021.
Headline financials
Revenue & EPS history
iTeos Therapeutics · Revenue · Quarterly
$35M
Forward guidance
iTeos anticipates a data-rich year in 2021 with trials ongoing for EOS-850 and EOS-448 and hopes to leverage its understanding of immune pathways to identify novel product candidates.
Tailwinds
- Advancement of immunotherapy pipeline.
- Ongoing trials for lead product candidates.
- Potential for data-rich year in 2021.
- Leveraging understanding of immune pathways.
- Identification of novel product candidates.
Headwinds
- Uncertainties inherent in clinical studies.
- Availability and timing of data from ongoing clinical trials.
- Risk of interim results not being predictive of final results.
- Uncertainties related to collaborations and strategic relationships.
- Impact of the COVID-19 pandemic.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 6 quarterly earnings reports
+0.8%
Avg return
Earnings day
+7.3%
Avg return
5 days after
+11.8%
Avg return
30 days after
38%
8 / 21 earnings
Positive
+39.6%
Q1 2024
Best reaction
-11.1%
Q4 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.2% | +0.0% | — | |
| Q1 2025 | -0.4% | +13.3% | +52.2% | |
| Q4 2024 | -3.7% | -6.4% | -11.4% | |
| Q3 2024 | -5.9% | -12.4% | -15.6% | |
| Q2 2024 | -3.4% | +1.4% | -3.1% | |
| Q1 2024 | +39.6% | +47.5% | +36.9% | |
| Q4 2023 | +5.1% | +8.0% | +12.0% | |
| Q3 2023 | -3.1% | — | — | |
| Q2 2023 | -2.6% | — | — | |
| Q1 2023 | -0.8% | — | — | |
| Q4 2022 | -7.7% | — | — | |
| Q3 2022 | +16.2% | — | — | |
| Q2 2022 | -9.4% | — | — | |
| Q1 2022 | +3.2% | — | — | |
| Q4 2021 | -3.6% | — | — | |
| Q3 2021 | +1.4% | — | — | |
| Q2 2021 | -1.5% | — | — | |
| Q1 2021 | +8.5% | — | — | |
| Q4 2020 | -11.1% | — | — | |
| Q3 2020 | -4.2% | — | — | |
| Q2 2020 | +0.0% | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro